Скачать или смотреть Replicor's Compassionate Access Program: Unlocking Hope for HBV/HDV Patients

In a groundbreaking development, Replicor Inc. has published data from its global compassionate access program in the Journal of Hepatology. This program, initiated with Dr. Marc Bourlière, focused on treating patients with chronic HBV/HDV infection and cirrhosis or decompensated cirrhosis. The access program treated 33 patients across 16 sites in 8 countries, showcasing remarkable results.
The highlights of this study are impressive: excellent safety of REP 2139-Mg, rapid symptom reversal, high cure rates for HDV and HBV, and the elimination of viruses from the liver within 10 weeks. Dr. Andrew Vaillant, CSO of Replicor, emphasizes the unique bifunctional nature of REP 2139, targeting HDV replication and subviral particle assembly.
This study sets the stage for phase IIA trials in Europe, offering hope to patients with HBV and HBV/HDV co-infection. Replicor, a privately held biopharmaceutical company, is dedicated to accelerating the development of effective treatments. Learn more about their mission and the latest advancements in the fight against HBV and HDV.